

concentrations but meclizine presented solubility issues and each drug differed.

For lisinopril, the goal was to develop a diluent and study the stability of the formulation. The stability of the drug was studied in the presence of amino acids as potential stabilizing agents. Analytical methods of sufficient sensitivity and specificity were performed on the selected formulations<sup>4</sup>.

Meclizine, a piperazine containing compound is a first-line drug for the prevention of motion sickness and management of vertigo. The solubility of meclizine in water is 0.1g/100mL. It is slightly soluble. The addition of chemically modified cyclodextrin to water can increase solubility due to hydrophobic pocket interactions. The addition of a concentration to a pH 4 citric acid buffer has demonstrated that combined with piperazine containing compounds allow

## Methods

Analytical procedures were validated in accordance with ICH Q2(R1) for the compound and a standard curve developed. Lisinopril was studied under the following conditions: three solutions were prepared in acetate buffer solution and stored at different temperatures. The remaining three solutions were prepared with buffer adjusted to pH 4.2 (with 100/100 and 50/50 glycine/alanine) to lisinopril. The lisinopril was stored for 210 days using HPLC.